{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:04:35Z","timestamp":1761516275702,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.4158\/ep15664.or","type":"journal-article","created":{"date-parts":[[2015,7,7]],"date-time":"2015-07-07T13:58:41Z","timestamp":1436277521000},"page":"1111-1116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Zoledronic Acid Therapy of Patients With Paget Disease of Bone Resistant to or With Unsustained Remission Following Prior Bisphosphonate Therapy"],"prefix":"10.1016","volume":"21","author":[{"given":"Joseph R.","family":"Tucci","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.4158\/EP15664.OR_bb0010","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jbmr.5650140215","article-title":"Discussion: Newer bisphosphonates in the treatment of Paget's disease of bone: where we are and where we want to go","volume":"14","author":"Grauer","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15664.OR_bb0015","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1385\/BMM:1:2:149","article-title":"Pharmacological management of Paget's disease of bone","volume":"I","author":"Papapoulos","year":"2002","journal-title":"Clin Rev Bone Miner Metab"},{"issue":"Suppl 2","key":"10.4158\/EP15664.OR_bb0020","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/jbmr.5650140216","article-title":"Paget's disease: acquired resistance to one aminobisphosphonate with retained response to another","volume":"14","author":"Gutteridge","year":"1999","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15664.OR_bb0025","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1002\/art.11136","article-title":"Bisphosphonate resistance in Paget's disease of bone","volume":"48","author":"Joshua","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.4158\/EP15664.OR_bb0030","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1136\/bmj.295.6609.1301","article-title":"Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD)","volume":"295","author":"Harinck","year":"1987","journal-title":"Brit Med J (Clin Res Ed)"},{"key":"10.4158\/EP15664.OR_bb0035","doi-asserted-by":"crossref","first-page":"91S","DOI":"10.1016\/S8756-3282(99)00074-5","article-title":"The use of risedronate in Paget's disease","volume":"24","author":"Miller","year":"1999","journal-title":"Bone"},{"key":"10.4158\/EP15664.OR_bb0040","first-page":"467","article-title":"Effect of multiple intravenous pamidronate courses in Paget's disease of bone","volume":"66","author":"Trombetti","year":"1999","journal-title":"Rev Rhum Engl Ed"},{"key":"10.4158\/EP15664.OR_bb0045","doi-asserted-by":"crossref","first-page":"423","DOI":"10.4158\/EP.7.6.423","article-title":"Intravenously administered pamidronate in the treatment of Paget's disease of bone","volume":"7","author":"Tucci","year":"2001","journal-title":"Endocr Pract"},{"issue":"Suppl 2","key":"10.4158\/EP15664.OR_bb0050","doi-asserted-by":"crossref","first-page":"P94","DOI":"10.1359\/jbmr.06s218","article-title":"Medical management of Paget's disease of bone: indications for treatment and review of current therapies","volume":"21","author":"Siris","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15664.OR_bb0055","first-page":"961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP15664.OR_bb0060","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/8756-3282(95)00282-1","article-title":"Tiludronate therapy for Paget's disease of bone","volume":"17","author":"McClung","year":"1995","journal-title":"Bone"},{"key":"10.4158\/EP15664.OR_bb0065","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(99)00062-5","article-title":"A randomized, double-blind comparison of risedronate and etidronate in the treatment of Paget's disease of bone. Paget's Risedronate\/Etidronate Study Group","volume":"106","author":"Miller","year":"1999","journal-title":"Am J Med"},{"key":"10.4158\/EP15664.OR_bb0070","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate in Paget's disease","volume":"353","author":"Reid","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4158\/EP15664.OR_bb0075","first-page":"10","article-title":"Guidelines on the management of Paget's disease of bone","volume":"31","author":"Bone and Tooth Society of Great Britain; National Association for the Relief of Paget's Disease","year":"2002","journal-title":"Bone"},{"key":"10.4158\/EP15664.OR_bb0080","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1359\/jbmr.070704","article-title":"Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone","volume":"22","author":"Merlotti","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15664.OR_bb0085","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/jbmr.5650081209","article-title":"Determinants of remission of Paget's disease of bone","volume":"8","author":"Patel","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15664.OR_bb0090","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1002\/jbmr.438","article-title":"A single infusion of zoledronic acid produces sustained remissions in Paget disease: data to 6.5 years","volume":"26","author":"Reid","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15664.OR_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0950-351X(97)80553-8","article-title":"Paget's disease of bone: clinical, pathogenetic and therapeutic aspects","volume":"11","author":"Papapoulos","year":"1997","journal-title":"Baillieres Clin Endocrinol Metab"},{"key":"10.4158\/EP15664.OR_bb0100","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S8756-3282(97)00222-6","article-title":"Paget's disease of bone: reduction of disease activity with oral risedronate","volume":"22","author":"Hosking","year":"1998","journal-title":"Bone"},{"key":"10.4158\/EP15664.OR_bb0105","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S8756-3282(99)00059-9","article-title":"Paget's disease of bone: treatment philosophy for the twenty-first century","volume":"24","author":"Siris","year":"1999","journal-title":"Bone"},{"key":"10.4158\/EP15664.OR_bb0110","doi-asserted-by":"crossref","first-page":"69S","DOI":"10.1016\/S8756-3282(99)00069-1","article-title":"Prediction and assessment of the response of Paget's disease to bisphosphonate treatment","volume":"24","author":"Hosking","year":"1999","journal-title":"Bone"},{"key":"10.4158\/EP15664.OR_bb0115","doi-asserted-by":"crossref","first-page":"P88","DOI":"10.1359\/jbmr.06s216","article-title":"Acquired resistance to bisphosphonates in Paget's disease of bone","volume":"21","author":"Papapoulos","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.4158\/EP15664.OR_bb0120","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1002\/art.1780231012","article-title":"Salmon calcitonin therapy for Paget's disease of bone. The problem of acquired clinical resistance","volume":"23","author":"Singer","year":"1980","journal-title":"Arth Rheum"},{"key":"10.4158\/EP15664.OR_bb0125","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/BF02509539","article-title":"High-dose pamidronate in the management of resistant Paget's disease","volume":"58","author":"Cundy","year":"1996","journal-title":"Calcif Tissue Internat"},{"key":"10.4158\/EP15664.OR_bb0130","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.bone.2003.12.011","article-title":"A randomized clinical trial comparing oral alendronate and intravenous pamidronate for the treatment of Paget's disease of bone","volume":"34","author":"Walsh","year":"2004","journal-title":"Bone"},{"issue":"Suppl 1","key":"10.4158\/EP15664.OR_bb0135","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.1016\/0169-6009(92)92327-M","article-title":"Risedronate in resistant Paget's disease of bone","volume":"17","author":"Kylstra","year":"1992","journal-title":"Bone"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20355270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20355270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:00:03Z","timestamp":1761516003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20355270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1530891X20355270"],"URL":"https:\/\/doi.org\/10.4158\/ep15664.or","relation":{},"ISSN":["1530-891X"],"issn-type":[{"type":"print","value":"1530-891X"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zoledronic Acid Therapy of Patients With Paget Disease of Bone Resistant to or With Unsustained Remission Following Prior Bisphosphonate Therapy","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP15664.OR","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}